Ionis Pharmaceuticals Inc. Sets Itself Up for Growth
Ionis Pharmaceuticals' (NASDAQ: IONS) third-quarter earnings were a bit humdrum considering partner Biogen (NASDAQ: BIIB) spilled the beans on sales of Spinraza a few weeks ago when it reported its earnings. Nevertheless, the biotech is setting itself up for solid growth with two additional drugs under review by regulators.
Metric
Q3 2017
Source: Fool.com
Ionis Pharmaceuticals Inc. Stock
€37.88
-0.290%
Our community is currently high on Ionis Pharmaceuticals Inc. with 20 Buy predictions and 5 Sell predictions.
With a target price of 56 € there is a positive potential of 47.84% for Ionis Pharmaceuticals Inc. compared to the current price of 37.88 €.
